Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2003-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1046/j.1538-7836.2003.00028.xPMID 12871552
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme*

  2002cited by this paper
• Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor.

  2002cited by this paper
• Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor.

  2002cited by this paper
• Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor*

  2000cited by this paper
• Inactivation of Active Thrombin-activable Fibrinolysis Inhibitor Takes Place by a Process That Involves Conformational Instability Rather Than Proteolytic Cleavage*

  2000cited by this paper
• The Molecular Weights, Mass Distribution, Chain Composition, and Structure of Soluble Fibrin Degradation Products Released from a Fibrin Clot Perfused with Plasmin*

  1999cited by this paper
• Catalytic activity of carboxypeptidase B and of carboxypeptidase Y with anisylazoformyl substrates.

  1999cited by this paper
• A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor*

  1998cited by this paper
• Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties*

  1998cited by this paper
• The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.

  1996cited by this paper
• Activation and characterization of procarboxypeptidase B from human plasma.

  1995cited by this paper
• Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*)

  1995cited by this paper
• Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen.

  1994cited by this paper
• Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma.

  1991cited by this paper
• High-efficiency transformation of mammalian cells by plasmid DNA.

  1987cited by this paper
• Structure of the potato inhibitor complex of carboxypeptidase A at 2.5-A resolution.

  1980cited by this paper
• Structure of potato inhibitor complex of carboxypeptidase A at 5.5-A resolution.

  1980cited by this paper
• Phospholipid-binding properties of bovine factor V and factor Va.

  1979cited by this paper

• Dependence of clot structure and fibrinolysis on apixaban and clotting activator

  2024cites this paper
• Functional Food Based on Potato

  2023cites this paper
• VhH anti‐thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow

  2022cites this paper
• Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

  2021cites this paper
• Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review

  2021influential citation
• A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor

  2019cites this paper
• Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity

  2018cites this paper
• THE ROLE OF ACTIVATED THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR (TAFIA) IN ATHEROSCLEROSIS PROGRESSION THE ROLE OF ACTIVATED THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR (TAFIA) IN ATHEROSCLEROSIS PROGRESSION By DHULFIHA MUZAFAR GANI, B.H.Sc. (Hons)

  2018cites this paper
• Discovery and characterization of novel cysteine-rich peptides in medicinal plants

  2018cites this paper
• Fibrinolysis inhibitors in plaque stability: a morphological association of PAI‐1 and TAFI in advanced carotid plaque

  2017cites this paper
• Physiological role of TAFI Attenuation of fibrinolysis

  2017cites this paper
• Changes in thrombin activatable fibrinolysis inhibitor and its role in normal pregnancy and pre-eclampsia

  2017cites this paper
• Structure‐function relationships in thrombin‐activatable fibrinolysis inhibitor

  2016cites this paper
• Impact of Thrombomodulin and Thrombin-Activatable Fibrinolysis Inhibitor on the Anticoagulant and Profibrinolytic Effects of Rivaroxaban

  2016cites this paper
• Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin‐activatable fibrinolysis inhibitor activation and activated thrombin‐activatable fibrinolysis inhibitor activity

  2016cites this paper
• The role of Thrombin Activatable Fibrinolysis Inhibitor in Abdominal Aortic Aneurysms

  2015cites this paper
• Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2014cites this paper
• Design and synthesis of conformationally restricted inhibitors of active thrombin activatable fibrinolysis inhibitor (TAFIa).

  2014cites this paper
• Model Systems to Explore CPB2 Pre-mRNA Splicing

  2014cites this paper
• Recovery of native protein from potato root water by expanded bed adsorption with amberlite XAD7HP

  2013cites this paper
• Thrombin Activatable Fibrinolysis Inhibitor: A Putative Target to Enhance Fibrinolysis

  2013cites this paper
• Insights into thrombin activatable fibrinolysis inhibitor function and regulation

  2013cites this paper
• ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES

  2012cites this paper
• Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th New Antithrombotic Drugs : Antithrombotic

  2012cites this paper
• Role of Heparin Binding in Plasmin-mediated Activation of TAFI and Thermal Stability of TAFIa

  2012cites this paper
• Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms

  2011cites this paper
• TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation

  2011cites this paper
• An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.

  2011cites this paper
• Thrombin-activatable fibrinolysis inhibitor and bacterial infections

  2011cites this paper
• Thrombin activatable fibrinolysis inhibitor

  2011cites this paper
• The role of the fibrinolytic system in arterial and venous thrombosis

  2010cites this paper
• Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

  2009cites this paper
• Functional Characterization of TAFI mutants Resistant to Activation by Thrombin, Thrombin- Thrombomodulin or Plasmin

  2009influential citation
• Potato Proteins, Lipids, and Minerals

  2009cites this paper
• Secretion and Antifibrinolytic Function of TAFI from Human Platelets

  2009cites this paper
• TAFI: A Potential Target for Fibrinolytic Drugs

  2009cites this paper
• Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation.

  2008cites this paper
• New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Binding of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) to Plasminogen May Play a Role in the Fibrinolytic Pathway

  2008cites this paper
• Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor

  2008cites this paper
• activated TAFI; A novel mechanism for enzyme auto-regulation Crystal structures of TAFI elucidate the inactivation mechanism of

  2008cites this paper
• A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma

  2007influential citation
• Metallocarboxypeptidases: emerging drug targets in biomedicine.

  2007cites this paper
• Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?

  2007cites this paper
• Discovery of thrombin activatable fibrinolysis inhibitor (TAFI)

  2006cites this paper
• Murine model of ferric chloride‐induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor

  2006cites this paper
• Generation of a Stable Activated Thrombin Activable Fibrinolysis Inhibitor Variant*

  2006cites this paper
• Discovery of thrombin activatable fibrinolysis inhibitor (TAFI)

  2006cites this paper
• A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) – Part II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis

  2006cites this paper
• A Carboxypeptidase Inhibitor from the Tick Rhipicephalus bursa

  2005cites this paper
• HISTORICAL SKETCH: The discovery of TAFI

  2005cites this paper
• Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease

  2005cites this paper
• Structural and functional studies on proteinaceous metallocarboxypeptidase inhibitors

  2005cites this paper
• Role of Kinetic Intermediates in the Folding of Leech Carboxypeptidase Inhibitor*

  2004cites this paper
• Secondary binding site of the potato carboxypeptidase inhibitor. Contribution to its structure, folding, and biological properties.

  2004cites this paper
• New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cites this paper
• Thrombin activatable fibrinolysis inhibitor: Not just an inhibitor of fibrinolysis

  2004cites this paper
• Mechanism of action of carboxypeptidase U: staying above the threshold

  2004cites this paper
• The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

  2004cites this paper
• The Intrinsic Threshold of the Fibrinolytic System Is Modulated by Basic Carboxypeptidases, but the Magnitude of the Antifibrinolytic Effect of Activated Thrombin-activable Fibrinolysis Inhibitor Is Masked by Its Instability*

  2004cites this paper
• Thrombin-activatable fibrinolysis inhibitor.

  2004cites this paper
• Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner

  2003cites this paper